INOVIQ's significant milestone in cancer diagnostics

INOVIQ (ASX:IIQ) has successfully completed disease specificity testing for its neuCA15-3 breast cancer detection test. The test, which combines a monoclonal antibody with INOVIQ's SubB2M detection reagent, offers enhanced sensitivity and specificity for breast cancer detection. It has been both analytically and clinically validated, showing promise in reducing false positives in non-cancer conditions.

Overview and future outlook for INOVIQ's breast cancer test

INOVIQ has achieved a crucial milestone in validating its neuCA15-3 test for breast cancer detection, showing high specificity and sensitivity. The test is set for commercialization as a Laboratory Developed Test in the US, with plans for scientific publication, platform transfer, and clinical studies. The company aims to enhance cancer diagnostics through its SubB2M technology and is preparing to partner with a US laboratory for market introduction. INOVIQ is focused on pioneering diagnostics that improve cancer detection and monitoring, aligning with the growing global demand for advanced breast cancer diagnostics.

Executive insights on breast cancer test breakthrough

The specificity testing is a critical milestone in the development of our neuCA15-3 breast cancer detection test, confirming its ability to differentiate breast cancer from other diseases,' said the CEO. 'This validation supports our plans to commercialize the test and make it available to clinicians and patients.